Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17378419 | 0.98 | ELANE (0.48) | ELANECYP2C9 | |
| SCHEMBL18880004 | 0.97 | ELANE (0.48) | ELANECYP2C9 | |
| SCHEMBL18880207 | 0.97 | ELANE (0.48) | ELANECYP2C9 | |
| SCHEMBL17378422 | 0.96 | ELANE (0.47) | ELANE | |
| SCHEMBL17378417 | 0.96 | ELANE (0.47) | ELANE | |
| SCHEMBL8223452 | 0.96 | ELANE (0.47) | ELANECYP2C9 | |
| SCHEMBL18880002 | 0.96 | ELANE (0.49) | ELANE | |
| SCHEMBL17378416 | 0.96 | ELANE (0.50) | ELANE | |
| SCHEMBL18880126 | 0.96 | ELANE (0.49) | ELANE | |
| SCHEMBL18880215 | 0.96 | ELANE (0.47) | ELANECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003858-A1 | MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | claimed |
| US-20110003858-A1 | MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-20110003858-A1 | MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003858-A1 | MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS | SERPINB1, ELANE, MPO | ELANE 2/4885CYP2C9 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.